top of page

Technical Considerations for Experimental Design (Part II)

Basic 2D monolayer cultures can fail to predict in vivo pharmaceutical candidate properties such as efficacy, ADME, or toxicity as they lack the necessary physical and biochemical cues found in vivo. MPS aim to fill this gap by exploiting advances in material sciences, microfabrication processes, and engineering to recreate the in vivo environment. In this session, technical design considerations of MPS are discussed with respect to:

- Material considerations
- Fluid dynamics in systems with flow
- Mechanical stimuli were applicable
- Device qualification and operation
- Body-on-a-chip configuration
- Immune cell incorporation

Date & Time

Thursday, August 24, 2023 at 1:00 PM ET

Duration

90 minutes

Agenda

Welcome and Introduction

James Gosset, Pfizer

Tom Chan, Boehringer Ingelheim Pharmaceuticals


Technical Considerations for Evaluating MPS: Materials Physical Cues, and Device Setup/Operation

Rebecca Hsia, Genentech


Technical Considerations for Evaluating MPS: Chip Linking, Immune Incorporation, and Readouts

Ratnakar Potla, Genentech-Roche


Q&A


Session Slides:


IQ MPS PharmTox Training Module 1 Sesssion 3 - Technical Considerations for Experimental D
.pdf
Download PDF • 7.17MB

Moderators and Presenters

Tom Chan

Senior Principal Scientist

Boehringer Ingelheim Pharmaceuticals Inc.

<h2 class="font_2"><strong>Tom Chan</strong></h2>
<p class="font_8">Senior Principal Scientist</p>
<p class="font_8">Boehringer Ingelheim Pharmaceuticals Inc.</p>

Dr. Chan leads a group of scientists who focus on the use of in vitro tools to assess clinical drug-drug interaction risk in drug development. He also represents the DMPK department on selected projects in development.

<h2 class="font_2"><strong>Tom Chan</strong></h2>
<p class="font_8">Senior Principal Scientist</p>
<p class="font_8">Boehringer Ingelheim Pharmaceuticals Inc.</p>

James Gosset

Associate Reseach Fellow

Pfizer, Inc.

James Gosset is an Associate Research Fellow at Pfizer responsible for DMPK and translational research in small molecule drug discovery and development. He is interested in the application of ADME predictive sciences and microphysiological systems as well as collaborating with developers to engineer platforms for ADME-based context of use.

<h2 class="font_2"><strong>Tom Chan</strong></h2>
<p class="font_8">Senior Principal Scientist</p>
<p class="font_8">Boehringer Ingelheim Pharmaceuticals Inc.</p>

Rebecca Hsia

Scientist

Genentech

Rebecca Hsia is a bioengineer who specializes in the design, clean room fabrication, and use of organ-on-chip technologies. He started his career in the Wyss Institute at Harvard University and now leads the biofabrication efforts in the Complex in Vitro Systems lab at Genentech.

Ratnakar Potla 

Principal Scientist

Genentech-Roche

Ratnakar Potla is a physician scientist by training. He is currently a principal scientist in the Complex in vitro systems group within Genentech Research and early development (gRED) where he leads the lung team within Safety assessment. He supports the safety assessment of candidate molecules using complex in vitro systems like organ on chips and organoids using multiple commercially available and in house fabricated platforms.

bottom of page